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Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen 
or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that 
can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical 
usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. 
Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients 
with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 
subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 
25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 
days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the 
intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 partici-
pants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants.
Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical as-
sessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 
and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed 
improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus.
Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain 
and significantly improves activities of daily living and physical and mental capabilities. 
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Chronic pain is defined as pain that persists beyond nor-
mal tissue healing time that is assumed to be 3 months by 
the International Association for the Study of Pain.1) Vari-
ous chronic pain problems include spinal pain, arthritis, 
ischemic pain syndromes, visceral pain syndromes, neuro-
pathic pain syndromes, and headache.2) It is an important 
and common medical problem around the world and a 
major reason for hospital visits. 
Pain-related medical expenses ranged from $560 bil-
lion to $635 billion in 2010, which was greater than those 
for coronary artery disease, cancer, and acquired immune 
deficiency syndrome (AIDS) in the United States. There-
fore, any increase in the cost should be suppressed through 
effective treatment.3) A World Health Organization (WHO) 
study on primary care patients in countries of Europe, 
North America, Africa, and Asia reported that 22% of 
patients complained of chronic pain that lasted for more 
than six months.4) A survey on 46,394 subjects in 15 Euro-
pean countries and Israel reported that 1 out of 5 persons 
suffered pain for 6 months,5) and 9% of the total popula-
tion in the United States experienced moderate or severe 
chronic non-cancerous pain.6) In an Australian study, the 
prevalence of chronic pain was 19.2%.7) Although much 
effort is being made to control chronic pain, causal treat-
ment is not possible in most cases and pain is difficult to 
be completely resolved. Thus, it is important to establish 
an appropriate goal for pain control rather than to expect a 
pain-free condition. Unless treated appropriately, pain may 
worsen the underlying disease and health-related quality 
of life, mental distress including anxiety, depression, and 
sleep disorder, and social problems including reduction in 
productivity and labor force.4) 
The use of opioids are recently recommended for 
those who do not gain adequate pain relief from the use of 
acetaminophen or nonsteroidal anti-inflammatory drugs 
(NSAIDs).8) Medical opioids can be administered in vari-
ous routes, and each route of administration has its own 
merits and demerits. Oral products are easy to administer, 
but difficult to use in patients with difficulty in oral intake. 
Demerits of intravenous (IV) injections include difficulty 
in vascular access, patient's pain associated with the use of 
a syringe, and the risk of stabbing. Transdermal products 
are designed to make up for such weaknesses of oral or IV 
products.
Among these opioids, fentanyl is a potent synthetic 
opioid analgesic with a short half-life that selectively acts 
on the μ-receptor, and its primary pharmacological ac-
tions are analgesic and sedative. Transdermal fentanyl 
matrix, with controlled release, extends the duration of 
action; it has been known that it takes 1.2 to 40 hours until 
minimal effective serum concentrations are produced and 
the steady state is maintained for 3 days.9) Plasma con-
centrations correlate with the delivery rate. According to 
Muijsers and Wagstaff,10) the mean maximum plasma con-
centration (Cmax) values of transdermal fentanyl patches 
at 34 to 38 hours after application were 0.6, 1.4, 1.7, and 2.5 
ng/mL, respectively, at a delivery rate of 25, 50, 75, and 100 
μg/hr, respectively.
This study is to evaluate the clinical usefulness of 
fentanyl matrix with respect to the long-term improve-
ment in pain and physical and mental functions.
METHODS
This study was conducted at 54 institutions in Korea from 
September 28, 2009 to December 15, 2010. A total of 1,355 
subjects used transdermal fentanyl matrix (Durogesic D-
trans Patch; Janssen Pharmaceuticals Korea, Seoul, Korea), 
and 639 (47.16%) of them completed the study. The re-
maining 716 subjects (52.84%) were withdrawn early due 
to loss to follow-up, adverse events (AEs), patient’s choice, 
pain relief or pain resolution, patient’s uncooperativeness, 
and others (Table 1). The mean age (± standard devia-
tion [SD]) of the subjects was 60.52 ± 13.18 years, ranging 
widely from 20 to 95 years). The mean height and weight 
were 161.30 ± 9.19 cm and 62.06 ± 10.82 kg, respectively. 
Patients who were suitable for inclusion criteria participat-
ed in the study. Inclusion criteria and exclusion criteria are 
Table 1. Causes of Dropout
Subjects and early  
dropout causes No. (%)
Total no. of subjects 1,335 (100)
Subjects who completed the study 639 (47.16)
Subjects who dropped out of the study early 716 (52.84)
    Lost to follow-up 289 (40.36)
    Adverse event 116 (16.20)
    Patient's choice 109 (15.22)
    Pain relief or pain resolution 90 (12.57)
    Patient’s uncooperativeness 22 (3.07)
    Consent withdrawal 7 (0.98)
    Protocol violation 4 (0.56)
    Judgment by investigator     1 (0.14)
    Others 78 (10.89)
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described in Table 2. If a patient discontinued the treat-
ment before the end of the study period, end-of-treatment 
assessment and follow-up assessment were performed.
Study subjects were patients who visited the par-
ticipating institutions with a complaint of non-cancerous 
chronic pain that was inadequately controlled despite 
treatment with opioids (such as tramadol, codeine, oral 
morphine, and oxycodone) and who were prescribed the 
fentanyl matrix by an investigator. The fentanyl matrix 
was administered for 6 months. Fentanyl matrix was not 
provided free of charge. The initial dose of the drug was 
determined based on the patient's opioid dose used as well 
as the degree of narcotic tolerance, patient’s general condi-
tion including body size, age, and degree of weakness, and 
medical condition. The initial dose for opioid-naive pa-
tients was 12 μg/hr. A fentanyl matrix dose conversion ta-
ble created based on the equianalgesic potency conversion 
and daily oral morphine dosage were referred to when oral 
or non-oral opioids were switched to the fentanyl matrix 
in opioid-experienced patients (Tables 3 and 4).11,12) If nec-
essary, the dose was reduced or increased to either 12 μg/
hr, 25 μg/hr, or 50 μg/hr to determine the minimum opti-
mal dose of the fentanyl matrix depending on the patient’s 
response and adjuvant analgesic demand.
The most common diagnosis was low back pain (125 
subjects, 27.72%), followed by spinal stenosis (98 subjects, 
21.73%), osteoarthritis (57 subjects, 12.64%), postoperative 
neuropathic pain (22 subjects, 4.88%), failed back surgery 
Table 2. Inclusion and Exclusion Criteria
Inclusion criteria
Aged 20 years or older
Complaining of chronic pain
Inadequate pain control despite previous treatment (e.g., tramadol, 
codeine, oral morphine, oxycodone)
Ability to complete the questionnaire judged by the investigator
Provision of written informed consent form
Exclusion criteria
Experience of treatment with fentanyl matrix within the past 4 weeks
Current or past history of drug or alcohol abuse
Likely to complain of pain more than necessary for actual pain on account 
of, e.g., traffic accident insurance
Cannot use transdermal analgesics due to skin disease
Serious mental disease
History of hypersensitivity to opioid analgesics
Chronic lung disease or respiratory failure 
Pregnant or possibly pregnant
Considered by the investigator to be ineligible to participate in this study 
based on warning, precaution, and contraindication in the package insert 
of fentanyl matrix
Considered by the investigator to be in a condition to threaten the 
patient’s well-being
Table 3. Equivalence of Opioids
Active 
substance
Equianalgesic dose (mg)
Intramuscular Oral
Morphine 10 30 (repeat dose) 60 (single dose or intermittent dose)
Hydromorphone 1.5 7.5
Methadone 10 20
Oxycodone 15 30
Levorphanol 2 4
Oxymorphone 1 10 (rectal)
Heroin 5 60
Meperidine 75 -
Codeine 130 200
Table 4. Table for Conversion of Oral Morphine to Fentanyl Matrix  
Oral morphine (mg/day) Fentanyl matrix dose (μg/hr)
< 135 25
135–224 50
225–314 75
315–404 100
405–494 125
495–584 150
585–674 175
675–764 200
765–854 225
855–944 250
945–1,034 275
1,035–1,124 300
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syndrome (FBSS; 17 subjects, 3.77%), and spinal cord in-
jury (14 subjects, 3.10%). While 294 subjects (65.19%) had 
no history of pain treatment, 157 subjects (34.81%) had a 
history of treatment. Regarding the previous treatments, 
nerve block was most common (74 subjects, 47.13%), fol-
lowed by an exercise therapy (60 subjects, 38.22%) and 
surgery (23 subjects, 14.65%) (Table 5).
Subjects made 2 to 4 visits (at 29 ± 7 days, 85 ± 14 
days, and 169 ± 14 days after administration, respectively) 
to have drug titration and submit clinical questionnaires. 
The intensity of pain and degree of interference with activ-
ities of daily life were assessed using Numeric Rating Scale 
(NRS). Mental function was assessed using the Korean 
version Beck Depression Inventory (K-BDI). Physical and 
mental health status were assessed by the Korean version 
Short-Form Health Survey 12 (SF-12). Patients and inves-
tigators respectively made global assessment of the effect 
of the drug at a visit compared with the previous visit on 
a 5-point scale themselves. In addition, the investigator’s 
Clinical Global Impression of Improvement (CGI-I) mea-
sured symptom improvement from baseline on a 7-point 
scale. Data from patients were analyzed by intention-to-
treat (ITT) analysis, full analysis set (FAS), and per-pro-
tocol (PP) analysis. Efficacy data were primarily analyzed 
by the FAS analysis in principle, and additional analysis 
was performed by the PP analysis. The FAS population for 
efficacy assessment included 451 subjects who met all of 
the inclusion criteria and none of the exclusion criteria, 
received at least one dose of the fentanyl matrix, and had 
primary efficacy endpoint measured at least once. The 451 
subjects consisted of 188 males (41.69%) and 263 females 
(58.31%). Safety of the drug were analyzed by the ITT 
analysis. The results were compared among the analyses 
(Fig. 1).
Patients who violated major inclusion/exclusion 
criteria, received no dose of the fentanyl matrix, or had no 
post-baseline efficacy data were excluded from the FAS 
population. The PP analysis included data from patients 
who were included in the ITT analysis and had completed 
all assessments at 24 ± 1 weeks after administration (169 
± 14 days) per protocol. However, patients who completed 
all assessments until 12 ± 1 weeks (85 ± 14 days) and then 
discontinued the treatment before the last assessment 
(169 ± 14 days) and those who completed all assessments 
scheduled for the last assessment at the time of discontinu-
ation were included in the PP analysis. Depending on the 
nature of efficacy endpoints, t-test, paired t-test, or non-
parametric tests of Wilcoxon signed-rank test, Wilcoxon 
rank-sum test, and chi-square test were used to test the 
difference from baseline.
For safety assessment, frequency and severity of AEs 
were investigated, and the rate of early withdrawal due to 
an AE was determined. For this, the ITT analysis was per-
formed using all data obtained from patients who received 
at least one dose of the fentanyl matrix. This analytical 
approach was applied to the AE data analysis as well. 
Frequency of abnormal behavior following the drug treat-
ment was also investigated.
Table 5. Characteristics of the Patients in the Full Analysis Set
Characteristic No. (%)
Total 451
Age (yr)
    Mean ± standard deviation 60.52 ± 13.18
    Median (range) 61 (20–95)
Age group
    20s 11 (2.44)
    30s 13 (2.88)
    40s 64 (14.19)
    50s 118 (26.16)
    60s 120 (26.61)
    70s 102 (22.62)
    80s 21 (4.66)
    ≥ 90s 2 (0.44)
Diagnosis
    Low back pain 125 (27.72)
    Spinal stenosis 98 (21.73)
    Osteoarthritis 57 (12.64)
    Postsurgical neuropathic pain 22 (4.88)
    Posttraumatic neuropathic pain 17 (3.77)
    Failed back surgery syndrome 17 (3.77)
    Spinal cord injury 14 (3.10)
    Rotator cuff tear 12 (2.66)
    Complex regional pain syndrome 10 (2.22)
    Diabetic neuropathy 5 (1.11)
    Post-stroke pain 2 (0.44)
    Postherpetic neuralgia 1 (0.22)
    Others 71 (15.74)
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RESULTS
In the FAS population, the mean initial dose was 13.43 ± 
4.10 μg/hr, and the mean dose at the end point was 15.87 
± 9.39 μg/hr, with an increase of 2.44 μg/hr. The mean du-
ration of administration was 105.15 ± 64.80 days, and the 
mean dose was 15.15 ± 7.72 μg/hr (range, 6.00 to 131.54 
μg/hr) (Table 6).
The mean ± SD pain intensity measured by NRS 
was 7.07 ± 1.78 at baseline and 4.93 ± 2.42 at the last as-
sessment, and the change in pain intensity from baseline to 
the last assessment was statistically significant (p < 0.001). 
Regarding the degree of improvement in pain intensity, 
improvement of 30% or more from baseline to the last as-
sessment was observed in 204 of 451 subjects (45%). 
The degree of interference with activities of daily 
life due to pain was assessed in 7 domains as follows. The 
NRS score in the general activity domain was 6.87 ± 2.22 
at baseline and was reduced by 2.1 to 4.77 ± 2.59 at the last 
assessment, and the change was statistically significant (p 
< 0.001). The NRS score in the mood domain was 6.83 ± 
2.28 at baseline and was reduced by 2.16 to 4.67 ± 2.73 at 
the last assessment, and the change was statistically sig-
nificant (p < 0.001). The NRS score in the ability to walk 
domain was 6.24 ± 2.79 at baseline and 4.33 ± 2.74 at the 
last assessment, showing statistically significant change (p 
< 0.001). The NRS score in the ability to perform normal 
work domain was 6.89 ± 2.28 at baseline, which was the 
highest score among 7 NRS domains, and was reduced by 
2.06 to 4.83 ± 2.60, and the change was statistically signifi-
cant (p < 0.001). The NRS score in the relations with oth-
ers domain was 5.91 ± 2.92 at baseline and was reduced by 
1.78 to 4.13 ± 2.71 at the last assessment. The change was 
smaller than that in other domains, but statistically signifi-
cant (p < 0.001). The NRS score in the sleep domain was 
6.07 ± 2.86 at baseline and 4.00 ± 2.91 at the last assess-
ment, showing statistically significant change (p < 0.001). 
The NRS score in enjoyment of life domain was 6.45 ± 2.72 
at baseline and 4.56 ± 2.83 at the last assessment, showing 
statistically significant change (p < 0.001) (Table 7). 
Changes in depression were measured using the 
K-BDI designed to assess the existence and severity of 
psychological and physiological symptoms of depression. 
Patients were asked to choose the statement that best 
represented their mood in 21 areas including sadness, 
pessimism, past failure, loss of pleasure, guilt feelings, 
punishment feelings, self-dislike, self-criticalness, suicidal 
thought, agitation, worthlessness, etc. The K-BDI score 
that was 0.96 ± 0.59 at baseline was changed by 0.21 ± 0.47 
1,355 Total enrolled subjects
1,355 Safety set (ITT)
451 Full analysis set (FAS)
160 Per-protocol set (PP)
1,355 Received at least one dose of fentanyl matrix
904 Excluded (including overlapped patients)
872 Received no more opioid analgesics during study
1 No pain
31 BDI measurement missing
291 Excluded
261 Early termination
30 Missed visit
Fig. 1. Efficacy and safety validation 
group. ITT: intention-to-treat, BDI: Beck 
Depression Inventory.
Table 6. Fentanyl Dose in Patients in the Full Analysis Set (n = 451)
Classification Mean ± SD Median (range)
Initial dose (μg/hr) 13.43 ± 4.10 12 (6–25)
Dose at the end point (μg/hr) 15.87 ± 9.39 12 (6–150)
Total dose administered 1,708.19 ± 1,702.84 1,500 (12–23,809)
Total duration of dosing (day) 105.15 ± 64.80 115 (1–197)
Mean dose (μg/hr) 15.15 ± 7.72 12 (6–131.54)
 SD: standard deviation.
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to 0.74 ± 0.54 at the last assessment. The change was statis-
tically significant (p < 0.001).
The SF-12 score was 31.60 ± 11.37 at baseline and 
was improved to 40.15 ± 11.13 at the last assessment, and 
the change was statistically significant (p < 0.001). The 
Physical Component Summary score was 28.94 ± 7.23 at 
baseline and was improved to 35.90 ± 10.25 at the last as-
sessment, and the change was statistically significant (p < 
0.001). The Mental Component Summary score was 35.80 
± 11.76 at baseline and 42.52 ± 10.58 at the last assess-
ment, also showing statistically significant improvement (p 
< 0.001).
On the global assessment by patients, 41 subjects 
(11.92%) and 82 subjects (23.84%) at the second visit and 
36 subjects (10.47%) and 82 subjects (23.84%) at the last 
assessment responded “not effective” and “slightly effec-
tive,” respectively. Meanwhile, 178 subjects (51.74%), 42 
subjects (12.21%), and 1 subject (0.29%) at the first assess-
ment and 161 subjects (46.80%), 44 subjects (12.79%), and 
21 subjects (6.10%) at the last assessment responded “ef-
fective,” “very effective,” and “extremely effective,” respec-
tively (Fig. 2). The increase in the number of subjects who 
responded the treatment was effective based on the global 
assessment was statistically significant (p = 0.001). On the 
global assessment by investigators, 14 investigators (8.75%) 
and 29 investigators (18.13%) at the second visit and 8 
investigators (5.00%) and 35 investigators (21.88%) at the 
last assessment responded “not effective” and “slightly ef-
fective,” respectively. Meanwhile, 87 investigators (54.38%), 
26 investigators (16.25%), and 4 investigators (2.50%) 
Table 7. Degree of Interference with Daily Life Activities (n = 451)
Variable Visit 1 Visit 2 Visit 3 Visit 4 p-value*
General activity < 0.001
    Mean ± SD 6.87 ± 2.22 5.65 ± 2.32 5.08 ± 2.47 4.77 ± 2.59
    Median (range) 7 (0–10) 6 (0–10) 5 (0–10) 5 (0–10)
Mood < 0.001
    Mean ± SD 6.83 ± 2.28 5.55 ± 2.42 4.98 ± 2.58 4.67 ± 2.73
    Median (range) 7 (0–10) 6 (0–10) 5 (0–10) 4 (0–10)
Ability to walk < 0.001
    Mean ± SD 6.24 ± 2.79 5.21 ± 2.62 4.68 ± 2.67 4.33 ± 2.74
    Median (range) 7 (0–10) 5 (0–10) 5 (0–10) 4 (0–10)
Ability to perform normal work < 0.001
    Mean ± SD 6.89 ± 2.28 5.72 ± 2.33 5.16 ± 2.47 4.83 ± 2.60
    Median (range) 7 (0–10) 6 (0–10) 5 (0–10) 5 (0–10)
Relations with others < 0.001
    Mean ± SD 5.91 ± 2.92 4.82 ± 2.64 4.42 ± 2.65 4.13 ± 2.71
    Median (range) 7 (0–10) 5 (0–10) 4 (0–10) 4 (0–10)
Sleep < 0.001
    Mean ± SD 6.07 ± 2.86 4.85 ± 2.72 4.27 ± 2.79 4.00 ± 2.91
    Median (range) 7 (0–10) 5 (0–10) 4 (0–10) 3 (0–10)
Enjoyment of life < 0.001
    Mean ± SD 6.45 ± 2.72 5.44 ± 2.62 4.81 ± 2.70 4.56 ± 2.83
    Median (range) 7 (0–10) 5 (0–10) 5 (0–10) 4 (0–10)
SD: standard deviation.
*Wilcoxon signed-rank test.
471
Lee et al. Long-term Application of Fentanyl Matrix for Chronic Non-Cancer Pain
Clinics in Orthopedic Surgery • Vol. 8, No. 4, 2016 • www.ecios.org
at the first assessment and 75 investigators (46.88%), 27 
investigators (16.88%), and 15 investigators (9.38%) at 
the last assessment responded “effective,” “very effective,” 
and “extremely effective,” respectively. The increase in the 
number of investigators who responded the treatment was 
effective based on the global assessment was statistically 
significant (p = 0.015) (Fig. 3).
On the 7-point scale CGI-I, “very much improved,” 
“much improved,” and “minimally improved” were con-
sidered improvement and the other answers were consid-
ered no improvement from baseline to the last assessment. 
Improvement was observed in 258 subjects (75.00%) at 
the first assessment and in 288 subjects (83.72%) at the last 
assessment. No improvement was observed in 86 subjects 
(25.00%) at the first assessment and in 56 subjects (16.28%) 
at the last assessment (p < 0.001). As in the FAS analysis, 
improvement at all efficacy endpoints was also significant 
in the PP analysis (Tables 8 and 9). 
In this study, 1,335 subjects who were administered 
at least one dose of fentanyl matrix were enrolled for the 
analysis of AEs and other safety data. These data were 
analyzed by the ITT analysis. A total of 279 cases of AEs 
occurred in 179 subjects (13.21%), and 228 cases of ad-
verse drug reactions occurred in 156 subjects (11.51%). 
AEs with an incidence of ≥ 1% were nausea (65 cases in 65 
subjects, 4.80%), dizziness (55 cases in 54 subjects, 3.99%), 
vomiting (43 cases in 41 subjects, 3.03%), and pruritus (22 
cases in 21 subjects, 1.55%). 
With regard to the relationship to the fentanyl ma-
trix, 27 cases (9.68%) were considered “not related,” 24 
cases (8.60%) “doubtful,” 107 cases (38.35%) “possible,” 
98 cases (35.13%) “probable,” and 23 cases (8.24%) “very 
likely.” With regard to the severity, 204 cases (73.12%) were 
"mild," 65 cases (23.30%) were "moderate," and 10 cases 
(3.58%) were “severe.” With regard to action taken after 
the occurrence of AEs of fentanyl matrix, there was “no 
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80
60
40
20
0
Last visit
100
A
Not effective
Slightly effective
1st visit
150
100
50
0
Last visit
200
B
Effective
Very effective
Extremely effective
41
82
36
178
42
1
161
44
21
82
Fig. 2. Global assessment by patients. (A) Not effective vs. slightly effective. (B) Effective vs. very effective vs. extremely effective.
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Fig. 3. Global assessment by investigators. (A) Not effective vs. slightly effective. (B) Effective vs. very effective vs. extremely effective.
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Table 8. Results of Per-Protocol Analysis (n = 160)
Variable Visit 1 Visit 2 Visit 3 Visit 4 p-value
Pain intensity < 0.001*
    Mean ± SD 7.46 ± 1.52 5.64 ± 1.80 4.66 ± 1.96 3.97 ± 2.09
    Median (range) 8 (3–10) 6 (0–10) 5 (1–10) 3.5 (0–9)
K-BDI < 0.001†
    Mean ± SD 1.11 ± 0.62 - - 0.62 ± 0.53
    Median (range) 1.05 (0–3) - - 0.48 (0–3)
General activity < 0.001*
    Mean ± SD 7.34 ± 1.56 5.59 ± 1.86 4.64 ± 2.06 3.91 ± 2.14
    Median (range) 8 (3–10) 6 (1–10) 4 (0–10) 4 (0–9)
Mood < 0.001*
    Mean ± SD 7.15 ± 1.92 5.31 ± 2.01 4.28 ± 2.18 3.57 ± 2.28
    Median (range) 7 (0–10) 5 (0–10) 4 (0–10) 3 (0–10)
Ability to walk < 0.001*
    Mean ± SD 6.93 ± 2.23 5.42 ± 2.22 4.52 ± 2.28 3.71 ± 2.30
    Median (range) 7 (0–10) 6 (0–10) 4 (0–10) 3 (0–9)
Ability to perform normal work < 0.001*
    Mean ± SD 7.40 ± 1.79 5.73 ± 1.92 4.79 ± 2.11 4.06 ± 2.21
    Median (range) 8 (1–10) 6 (1–10) 5 (0–10) 4 (0–10)
Relations with others < 0.001*
    Mean ± SD 6.71 ± 2.50 4.90 ± 2.20 4.14 ± 2.28 3.46 ± 2.29
    Median (range) 7 (0–10) 5 (0–10) 4 (0–10) 3 (0–10)
Sleep < 0.001*
    Mean ± SD 6.65 ± 2.54 4.66 ± 2.24 3.58 ± 2.25 3.00 ± 2.36
    Median (range) 7 (0–10) 5 (0–10) 3 (0–10) 2 (0–10)
Enjoyment of life < 0.001*
    Mean ± SD 7.03 ± 2.36 5.33 ± 2.10 4.31 ± 2.25 3.73 ± 2.45
    Median (range) 8 (0–10) 5 (0–10) 4 (0–10) 3 (0–10)
Assessment on pain intensity, K-BDI, and degree of interference with activities of daily life due to pain.
SD: standard deviation, K-BDI: Korean-Beck Depression Inventory.
*Wilcoxon signed-rank test. †Paired t-test.
Table 9. Proportion of Subjects with Improvement of 30% or More in Pain Intensity
Variable No. (%)
Confidence interval
Lower limit Upper limit
Improvement of ≥ 30% in pain intensity 204/451 (45) 0.38 0.52
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action” in 92 cases (32.97%), “dose modification” in 9 cases 
(3.23%), “temporary interruption” in 5 cases (1.79%), and 
“permanent discontinuation” in 173 cases (62.01%). 
DISCUSSION
Use of opioids for the treatment of chronic pain is impor-
tant in carefully selected patients. Representative opioid 
analgesics include methadone, oxycodone, fentanyl, hy-
dromorphone, morphine, codeine, and meperidine. These 
opioids are effective for pain control, but adverse reactions 
such as nausea, vomiting, constipation, headache and diz-
ziness have been frequently reported.4,13) Some studies have 
reported constipation and nausea as the most prevalent 
side effects.14) However, Yoo et al.15) argued that the great-
est problem with the use of such opioids is vague anxiety 
about opioids, which limits continuous use. Fentanyl ma-
trix, an opioid product, is a patch formulation developed 
to minimize gastrointestinal side effects of opioids.10) Allan 
et al.16) reported that transdermal fentanyl was preferred 
to sustained-release oral morphine by patients because it 
provided better pain relief, caused less constipation, and 
enhanced quality of life. Transdermal fentanyl has another 
advantage of allowing reduction in oral medication in 
elderly patients with chronic pain who take many medica-
tions. 
Fentanyl matrix is a transdermal drug delivery sys-
tem that steadily delivers fentanyl for 72 hours and has 
been reported to improve pain control and health-related 
quality of life in patients with non-cancerous chronic 
pain.10) Result of this study indicates that the long-term use 
of fentanyl matrix reduces pain intensity and significantly 
improves physical/mental functions including activities of 
daily life in patients with non-cancerous pain. With regard 
to the degree of improvement in pain intensity, improve-
ment of 30% or more from baseline to the last assessment 
was observed in 204 of 451 subjects (45%). 
In this study, 62.01% of the participants did neither 
come back to the clinics nor use the patches although 
AEs were only mild in them. It resulted in the decrease in 
the total number of subjects in the efficacy analysis. The 
results of our study were not significantly different from 
those in a previous study on fentanyl matrix.15) Insuf-
ficient use of opioid analgesics in patients with chronic 
non-cancerous pain has been mainly attributed to the fear 
of addiction, rather than AEs. Noble et al.17) showed in 
a meta-analysis that the rate of observed signs of opioid 
addiction was extremely low. Porter and Jick18) found 4 ad-
diction cases among 12,000 patients prescribed with opi-
oid analgesics, indicating that the long-term use of opioids 
are not associated with dependency. Nevertheless, Kissin19) 
claimed that there was no sufficient evidence to prove its 
safety against iatrogenic addiction among patients treated 
with opioids for chronic pain.
Recently, a new technique of fentanyl transdermal 
transport, fentanyl iontophoretic transdermal system 
(ITS), has been introduced. It is a patient-activated an-
algesic system indicated for the short-term management 
of acute postoperative pain in adult patients. Some study 
have shown that fentanyl ITS is an efficacious alternative 
to IV patient-controlled analgesia.20,21) Fentanyl ITS might 
be helpful as a next generation transdermal pain control. 
Still, transdermal fentanyl patch has been considered a 
useful pain controller in clinics. Some studies have report-
ed that transdermal fentanyl patches improve postopera-
tive pain relief and promote early functional recovery in 
total knee arthroplasty.22,23) 
The limitation of this study lies in the interpretation 
of analysis results as a large proportion of patients was ex-
cluded from the analysis due to violation of inclusion cri-
teria and dropping out of the study. It was an uncontrolled 
study, and no conclusion could be drawn on the efficacy. 
Active studies on the effective method of control of ad-
verse reactions after the use of opioids and improvement 
of patients’ recognition of opioid use are warranted in the 
future. 
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